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staging occurred, but were not different by study arm. 
Surgical resection rate was 49/71 in A, and 43/71 in B, with 
total margin status of 83 R0, 6 R1 and 3 R2, which by study 
arm was A 45:2:2 and B 38:4:1, p=0.6. Grades of AE, stoma-
related events, non-stoma-related surgical complications, 
and lab work were similar.  
Conclusions: Differences in surgical resection rates (69% vs. 
60%), R0 pathological margins (62% vs. 52%), and overall 
survival (63% and 55%) were not statistically significant, while 
relative safety was demonstrated for short-course RT. With a 
mean follow-up of 1.5 years, the preliminary results of this 
trial do not show a significant difference between 
randomization arms. An operability rate of 60% is important 
for a group of patients deemed inoperable/borderline at 
diagnosis in this group of developing countries.  
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Purpose/Objective: Single dose radiotherapy is standard 
treatment for painful bone metastases but the optimal dose 
remains incertain. This multi-centre, international, 
randomised radiotherapy trial compared a single dose of 8 Gy 
(n = 325) with that of 4 Gy (n = 326) to relieve pain arising 
from a single bone metastasis. 
Materials and Methods: Patients aged ≥ 18 years with bone 
pain, a histological diagnosis of malignancy, radiological 
evidence of bone metastasis at the site of pain and a life 
expectancy of ≥ 12 weeks were eligible. Exclusion criteria 
were myeloma, bone metastasis in previously irradiated sites, 
previous radioisotope treatment, or complicated bone 
metastasis. 
Pain relief at baseline, 4, 8, 12, 24 and 52 weeks was 
assessed using a Categorical Scale (CS) and a Visual Analogue 
Scale (VAS). The primary endpoint was the difference in the 
proportion of responders at 4 weeks.  
Results: There were 325 patients randomized to the 8Gy arm 
and 326 to the 4Gy arm with no significant difference in the 
distribution of demographic features or other co-variates 
between dose groups. 
Table 1 shows crude incidence of pain relief (all follow-ups) 
and prevalence at 4 weeks for CR, PR, NR and OR. There was 
a significant difference between dose groups when a global 
comparison was made for all follow-up times.. At the other 
intervals (8 to 52 weeks) both CRs and ORR was higher after 8 
Gy (statistically significant only at 8 weeks got CR; p = 0.03 
and at 8 and 52 weeks (p = 0.03 for ORTable 1 also 
summarises pain relief using the VAS method. Overall 
incidence and 4-week prevalence of pain relief was 
significantly higher after 8 Gy. 
The Kaplan-Meier actuarial rate (categorical scale) at 4 
weeks showed no significant difference in CR. The ORR was 
80% after 8 Gy compared to 68% after 4 Gy (log rank p = 
0.0015). 
A total of 117 of re-treatments were given of which 72 were 
in the 4 Gy dose group and 45 in the 8 Gy arm (p = 0.01). 
Table 1. Incidence (all follow-ups) and prevalence at 4 weeks 
of response to pain for patients with complete (CR), partial 
(PR), no (NR) and overall response (OR) using the categorical 
(CS) and visual analogue (VAS) scales. 
 
 
 
Conclusions: In a wide range of healthcare settings single 
dose radiotherapy is highly effective at achieving pain relief. 
Overall 8Gy is associated with a higher probability of pain 
relief from metastatic bone pain than 4Gy but there was still 
a high likelihood of pain response after the lower dose of 4 
Gy [71% (CS) and 82% VAS] although a significantly higher 
retreatment rate after 4Gy.  
   
OC-0192   
Optimal radiotherapy utilization rate in developing 
countries: an IAEA study 
E. Rosenblatt1, M. Barton10, W. Mackillop2, E. Fidarova1, L. 
Cordero3, J. Yarney4, C.C. Lim5, A. Abad6, V. Cernea7, S. 
Stojanovic-Rundic8, P. Strojan9, L. Kochbati11, A. Quarneti12 
1International Atomic Energy Agency, Nuclear Applications, 
Vienna, Austria  
2ICES-Queen's Health Services, Radiation Oncology, Kingston, 
Canada  
3Hospital Mexico, Radiotherapy, San Jose, Costa Rica  
4National Centre for Radiotherapy and Nuclear Medicine, 
Radiotherapy, Accra, Ghana  
5General Hospital Kuala Lumpur, Institute of Radiotherapy 
and Oncology, Kuala Lumpur, Malaysia 
6Lung Center of the Philippines Hospital, Radiation Oncology, 
Quezon City, Philippines  
7Oncology Institute Cluj-Napoca, Radiation Oncology, Cluj-
Napoca, Romania  
8Institute of Oncology and Radiology of Serbia, Radiation 
Oncology, Belgrade, Serbia  
9Institute of Oncology, Radiation Oncology, Ljubljana, 
Slovenia  
10Ingham Institute for Applied Medical Research, Radiation 
Oncology, Sydney, Australia  
11Institut National de Cancer Salah Azaiz, Radiotherapy, 
Tunis, Tunisia 
12Hospital Pereira Rossell, Radiotherapy, Montevideo, 
Uruguay  
 
